Stocks · Healthcare · Biotechnology
Galectin Therapeutics Inc. GALT
$3.90 +3.72% Close, Oct 2, 2026 · NASDAQ · Market cap $256.8M
Next earnings report: Nov 13, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is in an uptrend: above its 200-day average for 32 trading days, with the 50-day average above the 200-day.
- The stock is 40% below its highest close of the past year.
- The diluted share count rose 3.8% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 1%
- Accruals (lower is better)Top 3%
- Interest coverBottom 49%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 44%
- Free-cash-flow yieldBottom 46%
- EBITDA / enterprise valueTop 48%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 40%
- 6-month returnTop 21%
- 1-year return vs S&P 500Bottom 38%
- Distance from 52-week highBottom 34%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 20%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 41%
- Upside to consensus price targetTop 22%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 14%
- Maximum drawdown, 3 yearsBottom 32%
- Beta vs S&P 500 (lower is better)Top 7%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -1613.8% | — | Bottom 1% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -80.6%
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -2.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.02%
- Net buyback yield (TTM)
- -1.92%
- Shareholder yield
- -1.90%
- Share count change, 1 year
- +3.8%
- Share count change, 3-year CAGR
- +3.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 14, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -21.8%
- Average 2-day reaction, last 8
- -2.9%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $11.00
- Target vs current price
- +182.1%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 82%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 14, 2026 | -55.6% | -2.5% | +1.1% | +10.8% | — |
| May 15, 2026 | -33.3% | -7.7% | +7.2% | +13.6% | +33.2% |
| Mar 31, 2026 | +20.0% | +8.6% | -14.8% | -9.7% | +64.6% |
| Nov 14, 2025 | -18.2% | -0.4% | +3.8% | +13.0% | -50.1% |
| Aug 14, 2025 | +25.0% | +2.5% | +6.3% | +61.9% | +52.0% |
| May 15, 2025 | +25.0% | +1.5% | -1.5% | +3.1% | +198.5% |
| Mar 31, 2025 | -18.8% | -19.7% | -13.2% | -13.2% | +65.1% |
| Nov 14, 2024 | +10.0% | -5.2% | -2.8% | -31.4% | -54.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.14 | -$0.09 | -55.6% | — |
| May 15, 2026 | -$0.08 | -$0.06 | -33.3% | — |
| Mar 31, 2026 | -$0.08 | -$0.10 | +20.0% | — |
| Nov 14, 2025 | -$0.13 | -$0.11 | -18.2% | — |
| Aug 14, 2025 | -$0.12 | -$0.16 | +25.0% | — |
| May 15, 2025 | -$0.15 | -$0.20 | +25.0% | — |
| Mar 31, 2025 | -$0.19 | -$0.16 | -18.8% | $36,000 |
| Nov 14, 2024 | -$0.18 | -$0.20 | +10.0% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -6.19% | — | — | Bottom 46% |
| Earnings yield | -10.95% | — | — | Bottom 44% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 11
- Days above the 200-day average
- 32
- 50-day average slope (20 days)
- -4.6%
- 200-day average slope (20 days)
- -5.4%
- Distance from 50-day average
- +4.8%
- Distance from 200-day average
- +19.5%
- RSI (14)
- 50.2
- Relative volume
- 0.72×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 86.8%
- Volatility vs own 5-year history
- 66th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.27
- Correlation with S&P 500
- 0.04
- Current drawdown from 1-year high
- -40.1%
- Maximum drawdown, 3 years
- -80.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 28, 2021 | Dec 24, 2024 | -83.5% | 921 days | 177 days (Sep 11, 2025) |
| Dec 15, 2025 | May 19, 2026 | -68.0% | 106 days | Not yet recovered |
| Sep 28, 2020 | Jan 29, 2021 | -46.2% | 85 days | 58 days (Apr 23, 2021) |
| Sep 11, 2025 | Oct 1, 2025 | -29.6% | 14 days | 23 days (Nov 3, 2025) |
| Nov 18, 2025 | Nov 21, 2025 | -13.6% | 3 days | 8 days (Dec 4, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $256.8M
- EPS, diluted (TTM)
- -$0.43
- Revenue (TTM)
- $0
- 52-week range
- $2.03 – $7.13
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| Net income | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| EPS (diluted) | -$0.52 | -$0.65 | -$0.74 | -$0.76 | -$0.48 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$11.2M | -$12.0M | -$9.6M | -$7.5M | -$8.2M | -$5.5M | -$5.0M | -$9.1M |
| EPS (diluted) | -$0.18 | -$0.19 | -$0.15 | -$0.12 | -$0.13 | -$0.08 | -$0.08 | -$0.14 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M |
| Dividends paid | -$171,000 | $0 | $0 | -$91,000 | $0 |
| Net share buybacks | $6.8M | $0 | $0 | $1.2M | $5.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $13.3M
- Total assets
- $14.8M
- Total liabilities
- $151.7M
- Total debt
- $137.7M
- Net debt
- $124.4M
- Shareholders’ equity
- -$136.9M
As of Jun 30, 2026 (filed Aug 14, 2026).
Short interest
- Shares sold short
- 9,335,305
- Days to cover
- 25.16
- Change vs previous report
- +2.9%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Mar 23, 2012
- 1-for-6